BioSpace News Archive

T-Therapeutics, a biotechnology company developing next-generation soluble TCR therapeutics targeting cancer and autoimmune indications, announces the appointment of biopharma industry veteran Dr David Hung as Chairman of its Board of Directors.

LEO Pharma Inc. announced the availability of the Adtralza® pre-filled pen in Canada. Adtralza is currently indicated in patients 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.1 Prior to the introduction of the pre-filled pen, Adtralza was only available in a 1 mL pre-filled syringe.

Treating prostate cancer with immunotherapy is currently difficult to do. But preliminary results from a first in-human phase 1 trial using a chimeric antigen receptor T cell therapy developed by researchers from City of Hope® showed that patients with advanced prostate cancer had minimal side effects with the cellular immunotherapy and had promising therapeutic activity, according to a study published in Nature Medicine.

A team of investigators at City of Hope funded by the Prostate Cancer Foundation reports that patients with advanced prostate cancer can be safely treated with chimeric antigen receptor T cell therapy.

Avidity Biosciences, Inc. announced positive initial AOC 1020 data from the Phase 1/2 FORTITUDE™ trial demonstrating unprecedented and consistent reductions of greater than 50% in DUX4 regulated genes, trends of functional improvement, and favorable safety and tolerability in people living with facioscapulohumeral muscular dystrophy.

REGENXBIO Inc. announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024.

Ochre Bio, a pioneer in chronic liver disease medicine development, has announced the start of a multi-year data licence agreement with GSK.

Foundation Medicine, Inc., announced that it has formed a collaboration with Repare Therapeutics, a leading clinical-stage precision oncology company, to provide prospective genomic profiling to patients in Repare’s ongoing Phase I/Ib MYTHIC study of lunresertib alone or in combinations in genomically-defined patient populations.

Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced plans to proceed to a Phase 2b registration trial of its lead investigational product ATX101.

Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning platform with multiple clinical-stage drug programs, announced that the Japan Patent Office has issued a Certificate of Patent for patent application no. 2021-513267 / registration no. 7489966 directed to Lantern Pharma’s drug candidate LP-284.